# Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

> **NCT06328179** · NA · RECRUITING · sponsor: **Huai'an First People's Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；

## Key facts

- **NCT ID:** NCT06328179
- **Lead sponsor:** Huai'an First People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-24
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328179, "Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06328179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*